VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market

Core Insights - VivoSim Labs, Inc. has emerged from stealth mode to significantly impact drug discovery and development [1] - The FDA's initiative to phase out animal testing in favor of non-animal methodologies is expected to accelerate VivoSim's market adoption, targeting a market worth over $10 billion [2][7] Company Overview - VivoSim will provide liver and intestinal toxicology insights using its new approach methodologies (NAM) models, which are designed to be more predictive and ethically sound compared to traditional animal testing [2][3] - The company aims to reduce clinical trial failures and development costs by 50% across the industry through its innovative models [4] Technological Advancements - VivoSim's NAMkind liver model has shown an industry-best correlation rate with known clinical failures, potentially reducing the incidence of unforeseen liver toxicity events by 50% or more [5] - The NAMkind intestine models will offer insights currently unavailable to industry scientists, addressing issues that can affect cancer patients undergoing treatment [6] Industry Impact - The FDA's goals to phase out animal testing create a significant opportunity for VivoSim to fill the gap in commercially available solutions, aligning with the vision of providing better outcomes for pharmaceutical customers and patients [7]